Adaptive Radiotherapy Based on Multi-Parametric Diffusion- and Perfusion-weighted Magnetic Resonance Imaging in Patients With Newly Diagnosed High-Grade Glioma

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to find out if performing additional Magnetic Resonance Image (MRI) scans of the subjects' brain during each week of the radiation treatment of their high-grade glioma will help improve the radiation treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Histopathologically proven diagnosis of glioblastoma, anaplastic astrocytoma, or anaplastic oligodendroglioma

• History and physical examination within 28 days prior to enrollment

• Karnofsky performance status 70 or greater

• Age 18 years or greater

• Negative pregnancy test for females of childbearing potential before 1st research MRI, performed in accordance to institutional guidelines.

• Plan to receive 59.4-60 Gy in 30-33 fractions of radiotherapy. Glioblastoma patients over 65 year-old can receive hypofractionated radiotherapy including 40 Gy in 15 fractions.

Locations
United States
New York
Columbia University Irving Medical Center/NYPH
RECRUITING
New York
Contact Information
Primary
Tony J. Wang, MD
tjw2117@cumc.columbia.edu
212-305-5050
Backup
Radiation Oncology Research Department
212-305-5050
Time Frame
Start Date: 2024-01-30
Estimated Completion Date: 2027-12
Participants
Target number of participants: 20
Treatments
Experimental: Adaptive Radiotherapy
Subjects will receive radiotherapy per standard of care over 30-33 once-daily fractions in addition to 7 brain MRIs each in every week of treatment. Subjects receiving hypofractionated radiotherapy will receive radiotherapy per standard of care over 15 once-daily fractions in addition to 4 brain MRIs each in every week of treatment.
Sponsors
Leads: Columbia University
Collaborators: Varian Medical Systems

This content was sourced from clinicaltrials.gov